Who are Alimta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytalux, Cytalux, Flotufolastat (18F), Mirvetuximab soravtansine plus Bevacizumab, OTL38 for Injection, AFOLIA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pemetrexed.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Alimta — Competitive Intelligence Brief

Alimta (pemetrexed) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Folate Analog Metabolic Inhibitor. Area: Oncology.

marketed Folate Analog Metabolic Inhibitor Folate receptor alpha Oncology Live · refreshed every 30 min

Target snapshot

Alimta (pemetrexed) — Actavis. Alimta works by inhibiting the enzyme dihydrofolate reductase, which is necessary for DNA synthesis and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alimta TARGET	pemetrexed	Actavis	marketed	Folate Analog Metabolic Inhibitor	Folate receptor alpha	2004-01-01
Cytalux	PAFOLACIANINE	On Target Labs	marketed	Optical Imaging Agent	Folate receptor alpha	2021-01-01
Cytalux	Cytalux	Ann & Robert H Lurie Children's Hospital of Chicago	marketed		Folate receptor alpha
Flotufolastat (18F)	Flotufolastat (18F)	Blue Earth Diagnostics	marketed	Folate receptor-targeted PET imaging agent	Folate receptor alpha (FR-α)
Mirvetuximab soravtansine plus Bevacizumab	Mirvetuximab soravtansine plus Bevacizumab	AbbVie	phase 3	Antibody-drug conjugate (mirvetuximab soravtansine) + monoclonal antibody (bevacizumab)	Folate receptor alpha (FRA) and VEGF
OTL38 for Injection	OTL38 for Injection	On Target Laboratories, LLC	phase 3	Antibody-drug conjugate (ADC)	Folate receptor alpha (FRA)
AFOLIA	AFOLIA	Fertility Biotech AG	phase 3		Folate receptor alpha (FRα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-10-28 — Alimta · 9604990 · Compound · US
2036-02-19 — Alimta · 12115164 · Method of Use · US
2036-02-19 — Alimta · 11793813 · Formulation · US

Sponsor landscape (Folate Analog Metabolic Inhibitor class)

Actavis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alimta — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab